These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36780840)

  • 1. CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance.
    Abavisani M; Khayami R; Hoseinzadeh M; Kodori M; Kesharwani P; Sahebkar A
    Drug Resist Updat; 2023 May; 68():100948. PubMed ID: 36780840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance.
    Rafiq MS; Shabbir MA; Raza A; Irshad S; Asghar A; Maan MK; Gondal MA; Hao H
    BioDrugs; 2024 May; 38(3):387-404. PubMed ID: 38605260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR-Cas inhibits plasmid transfer and immunizes bacteria against antibiotic resistance acquisition in manure.
    Upreti C; Kumar P; Durso LM; Palmer KL
    Appl Environ Microbiol; 2024 Sep; 90(9):e0087624. PubMed ID: 39158272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention and control of antimicrobial resistance using CRISPR-Cas system: a review].
    Wang C; Liu Z; Tang B; Yang H; Sun D
    Sheng Wu Gong Cheng Xue Bao; 2022 Apr; 38(4):1432-1445. PubMed ID: 35470617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR in Modulating Antibiotic Resistance of ESKAPE Pathogens.
    Saha U; Gondi R; Patil A; Saroj SD
    Mol Biotechnol; 2023 Jan; 65(1):1-16. PubMed ID: 35939207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Application of the CRISPR-Cas System in Antibiotic Resistance.
    Tao S; Chen H; Li N; Liang W
    Infect Drug Resist; 2022; 15():4155-4168. PubMed ID: 35942309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing prokaryotic clustered regularly interspaced short palindromic repeats-Cas adaptive immune system to combat antimicrobial resistance.
    Devi V; Harjai K; Chhibber S
    Future Microbiol; 2023 May; 18():443-459. PubMed ID: 37317864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressing the CRISPR/Cas adaptive immune system in bacterial infections.
    Gholizadeh P; Aghazadeh M; Asgharzadeh M; Kafil HS
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2043-2051. PubMed ID: 28601970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CRISPR-Cas systems and anti-CRISPR proteins in bacterial antibiotic resistance.
    Kadkhoda H; Gholizadeh P; Samadi Kafil H; Ghotaslou R; Pirzadeh T; Ahangarzadeh Rezaee M; Nabizadeh E; Feizi H; Aghazadeh M
    Heliyon; 2024 Jul; 10(14):e34692. PubMed ID: 39149034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections.
    Wu Y; Battalapalli D; Hakeem MJ; Selamneni V; Zhang P; Draz MS; Ruan Z
    J Nanobiotechnology; 2021 Dec; 19(1):401. PubMed ID: 34863214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in CRISPR-Cas systems for human bacterial disease.
    Mathuria A; Vora C; Ali N; Mani I
    Prog Mol Biol Transl Sci; 2024; 208():19-41. PubMed ID: 39266183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of clustered regularly interspaced short palindromic repeats and their associated Cas proteins (CRISPR/Cas) systems in multiple sequenced strains of Klebsiella pneumoniae.
    Ostria-Hernández ML; Sánchez-Vallejo CJ; Ibarra JA; Castro-Escarpulli G
    BMC Res Notes; 2015 Aug; 8():332. PubMed ID: 26238567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitizing pathogens to antibiotics using the CRISPR-Cas system.
    Goren M; Yosef I; Qimron U
    Drug Resist Updat; 2017 Jan; 30():1-6. PubMed ID: 28363331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the Interplay of the CRISPR-CAS System with Antibiotic Resistance in
    Shabbir MAB; Ul-Rahman A; Iftikhar MR; Rasheed M; Maan MK; Sattar A; Ahmad M; Khan FA; Ahmad W; Riaz MI; Aslam HB
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256391
    [No Abstract]   [Full Text] [Related]  

  • 15. How CRISPR-Cas System Could Be Used to Combat Antimicrobial Resistance.
    Gholizadeh P; Köse Ş; Dao S; Ganbarov K; Tanomand A; Dal T; Aghazadeh M; Ghotaslou R; Ahangarzadeh Rezaee M; Yousefi B; Samadi Kafil H
    Infect Drug Resist; 2020; 13():1111-1121. PubMed ID: 32368102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance.
    Mayorga-Ramos A; Zúñiga-Miranda J; Carrera-Pacheco SE; Barba-Ostria C; Guamán LP
    ACS Infect Dis; 2023 Jul; 9(7):1283-1302. PubMed ID: 37347230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing the CRISPR-Cas Systems to Combat Antimicrobial Resistance.
    Duan C; Cao H; Zhang LH; Xu Z
    Front Microbiol; 2021; 12():716064. PubMed ID: 34489905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas and Restriction-Modification Act Additively against Conjugative Antibiotic Resistance Plasmid Transfer in Enterococcus faecalis.
    Price VJ; Huo W; Sharifi A; Palmer KL
    mSphere; 2016; 1(3):. PubMed ID: 27303749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria.
    Yosef I; Manor M; Kiro R; Qimron U
    Proc Natl Acad Sci U S A; 2015 Jun; 112(23):7267-72. PubMed ID: 26060300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems.
    Gomaa AA; Klumpe HE; Luo ML; Selle K; Barrangou R; Beisel CL
    mBio; 2014 Jan; 5(1):e00928-13. PubMed ID: 24473129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.